Bradmer Pharmaceuticals Inc. has not sought any endorsements from the organizations listed below.  These organizations are viewed by management as having information or resources which may be helpful to patients with Glioblastoma Multiforme or other forms of brain cancer.  Note that clicking on the links below will cause you to leave the Bradmer website; Bradmer can not be held responsible for information found on such sites.


American Brain Tumor Association
Please visit this site which contains helpful literature for brain cancer patients and their families.
http://hope.abta.org

 

Accelerate Brain Cancer Cure
ABC2 maintains a comprehensive list of links to medical information, clinical trials, industry publications, and other valuable resources.
http://www.abc2.org/general_links.shtml

 

Musella Foundation For Brain Tumor Research & Information, Inc.
Provides patient education resources, helps match patients to clinical trials, and raises funds for brain tumor research.
http://www.virtualtrials.com

Duke University Medical Center
The Preston Robert Tisch Brain Tumor Center
Duke University and Bradmer have partnered with a goal of completing the clinical testing and commercialization of Neuradiab, a promising new therapy for brain cancer. 
http://www.cancer.duke.edu/btc


National Brain Tumor Foundation
The National Brain Tumor Foundation has been a resource to the brain tumor community since 1981.  NBTF provides detailed, reliable information to patients and families and a variety of free support and education programs.  The organization also funds innovative research through its research grant program.
http://www.braintumor.org


Participation in Bradmer-Sponsored Clinical Trials
Enrollment is underway for the Phase III GLASS-ART Trial testing Neuradiab (formerly referred to in literature as I-131 Labeled Anti-Tenascin Monoclonal Antibody 81C6).   Cancer centers across the United States are participating in this trial for patients with newly diagnosed Glioblastoma Multiforme.    Please call 888-267-0707 x1 or visit www.glassarttrial.com for more information.